FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940824932> ?p ?o ?g. }

• W2940824932 abstract "No effective treatments currently exist for fibrodysplasia ossificans progressiva (FOP) patients, and disease progression results in severe restriction of joint function and premature mortality. LDN-193189 has been demonstrated to be efficacious in a mouse FOP disease model after oral administration. To support species selection for drug safety evaluation and structure optimization for back-up compounds, in vitro metabolism of LDN-193189 was investigated in liver microsomes and cytosols of mouse, rat, dog, rabbit, monkey and human. To evaluate the formation of potential reactive intermediates, nucleophilic trapping agents, such as glutathione (GSH) and potassium cyanide (KCN), were added to the incubation mixtures fortified with NADPH. The formation of non-P450 mediated metabolite(s) in cytosols of various species was also investigated in the presence of inhibitors for aldehyde oxidase (AO) and xanthine oxidase (XO). Metabolite profiles and metabolic soft spots of LDN-193189 were elucidated using LC/UV and mass spectral techniques. LDN-193189 presented a significant dependence upon AO for its metabolic clearance, forming the major M422c metabolite, which will result in significant variability in exposure values in different species as well as among different human subjects. The piperazinyl moiety was the target of NADPH-dependent metabolism generating, among the metabolites, reactive iminium intermediates confirmed through trapping and aniline metabolites (M337 and M380), which brought up concerns on the drug safety. Therefore, blocking the AO mediated metabolic site and changing the piperazinyl moiety may lead to a more metabolically stable and less toxic compound while retaining pharmacological activity, culminating in the discovery of new lead compounds, such as TRND506894. The results from this study have provided very valuable information to guide the structure optimization and demonstrated the importance of metabolite identification in the drug discovery of novel and safe drug candidates." @default.
• W2940824932 created "2019-05-03" @default.
• W2940824932 creator A5017833659 @default.
• W2940824932 creator A5018297543 @default.
• W2940824932 creator A5018433143 @default.
• W2940824932 creator A5023193081 @default.
• W2940824932 creator A5025894524 @default.
• W2940824932 creator A5040541322 @default.
• W2940824932 creator A5049639928 @default.
• W2940824932 creator A5051297026 @default.
• W2940824932 creator A5059600333 @default.
• W2940824932 creator A5066287008 @default.
• W2940824932 creator A5091429263 @default.
• W2940824932 creator A5091773218 @default.
• W2940824932 date "2019-04-24" @default.
• W2940824932 modified "2023-10-16" @default.
• W2940824932 title "Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)" @default.
• W2940824932 cites W109496764 @default.
• W2940824932 cites W1583077790 @default.
• W2940824932 cites W189176051 @default.
• W2940824932 cites W1972416867 @default.
• W2940824932 cites W1974534288 @default.
• W2940824932 cites W1977368300 @default.
• W2940824932 cites W1981995525 @default.
• W2940824932 cites W1984470879 @default.
• W2940824932 cites W1995913255 @default.
• W2940824932 cites W2012836529 @default.
• W2940824932 cites W2022710899 @default.
• W2940824932 cites W2025411649 @default.
• W2940824932 cites W2029353929 @default.
• W2940824932 cites W2033545087 @default.
• W2940824932 cites W2041417337 @default.
• W2940824932 cites W2041814673 @default.
• W2940824932 cites W2041916231 @default.
• W2940824932 cites W2047642636 @default.
• W2940824932 cites W2049355783 @default.
• W2940824932 cites W2059460453 @default.
• W2940824932 cites W2064395979 @default.
• W2940824932 cites W2065071209 @default.
• W2940824932 cites W2068532562 @default.
• W2940824932 cites W2073197214 @default.
• W2940824932 cites W2080116174 @default.
• W2940824932 cites W2082152178 @default.
• W2940824932 cites W2085613305 @default.
• W2940824932 cites W2120774219 @default.
• W2940824932 cites W2125227595 @default.
• W2940824932 cites W2132418617 @default.
• W2940824932 cites W2133600149 @default.
• W2940824932 cites W2145304853 @default.
• W2940824932 cites W2147130089 @default.
• W2940824932 cites W2154767933 @default.
• W2940824932 cites W2156168853 @default.
• W2940824932 cites W2165766992 @default.
• W2940824932 cites W2166501048 @default.
• W2940824932 cites W2187451625 @default.
• W2940824932 cites W2278281289 @default.
• W2940824932 cites W2296680467 @default.
• W2940824932 cites W2314930650 @default.
• W2940824932 cites W2315149444 @default.
• W2940824932 cites W2315921289 @default.
• W2940824932 cites W2402101036 @default.
• W2940824932 cites W2429846549 @default.
• W2940824932 cites W2530388172 @default.
• W2940824932 cites W2558958398 @default.
• W2940824932 cites W2563430249 @default.
• W2940824932 cites W2581481137 @default.
• W2940824932 cites W2591993056 @default.
• W2940824932 cites W2605332436 @default.
• W2940824932 cites W2625396153 @default.
• W2940824932 cites W2891182946 @default.
• W2940824932 cites W3175318380 @default.
• W2940824932 cites W990126594 @default.
• W2940824932 doi "https://doi.org/10.3389/fphar.2019.00234" @default.
• W2940824932 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6491728" @default.
• W2940824932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31068801" @default.
• W2940824932 hasPublicationYear "2019" @default.
• W2940824932 type Work @default.
• W2940824932 sameAs 2940824932 @default.
• W2940824932 citedByCount "7" @default.
• W2940824932 countsByYear W29408249322019 @default.
• W2940824932 countsByYear W29408249322020 @default.
• W2940824932 countsByYear W29408249322021 @default.
• W2940824932 countsByYear W29408249322023 @default.
• W2940824932 crossrefType "journal-article" @default.
• W2940824932 hasAuthorship W2940824932A5017833659 @default.
• W2940824932 hasAuthorship W2940824932A5018297543 @default.
• W2940824932 hasAuthorship W2940824932A5018433143 @default.
• W2940824932 hasAuthorship W2940824932A5023193081 @default.
• W2940824932 hasAuthorship W2940824932A5025894524 @default.
• W2940824932 hasAuthorship W2940824932A5040541322 @default.
• W2940824932 hasAuthorship W2940824932A5049639928 @default.
• W2940824932 hasAuthorship W2940824932A5051297026 @default.
• W2940824932 hasAuthorship W2940824932A5059600333 @default.
• W2940824932 hasAuthorship W2940824932A5066287008 @default.
• W2940824932 hasAuthorship W2940824932A5091429263 @default.
• W2940824932 hasAuthorship W2940824932A5091773218 @default.
• W2940824932 hasBestOaLocation W29408249321 @default.
• W2940824932 hasConcept C105702510 @default.
• W2940824932 hasConcept C181199279 @default.
• W2940824932 hasConcept C185592680 @default.

• next